ModifiedPremera BluecrossPolicy G2153

Pancreatic Enzyme Testing for Acute Pancreatitis

This policy governs reimbursement and coverage criteria for serum and urine pancreatic enzyme testing (including amylase, lipase, trypsinogen/TAP, and selected biomarkers) for diagnosis, assessment, and management of acute pancreatitis for Premera Bluecross members.

Policy Summary

PayerPremera Bluecross

PolicyPancreatic Enzyme Testing for Acute Pancreatitis

Policy CodePolicy G2153

Change TypeMaterial — added routine test management language

Effective DateFeb 6, 2026

Next Review Date

Key ActionOrder serum lipase alone for suspected acute pancreatitis when available; avoid concurrent amylase or routine repeat testing without new clinical indication.

SourceLink

POLICY UPDATE CHANGES

Measurement of serum lipase or amylase concentration may be considered reimbursable for individuals presenting with signs and symptoms of acute pancreatitis; any other use of this testing is not reimbursable.

lipase preferredLipase preferred

3x URLDiagnostic threshold

not reimbursable listExcluded tests

once per visitOnce per visit

9.3%

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Estimated unnecessary tests

Coverage Criteria for Pancreatic Enzyme Testing

Unsupported block type: object

Coding and Diagnostic Thresholds

Prior Authorization

Provider-action / Billing guidance (callout)

Professional guidance and policy expectations for ordering pancreatic enzyme tests: 1) Prior authorization awareness — Providers should be aware that concurrent or serial ordering of both lipase and amylase, or repeated serial enzyme testing, may prompt utilization review and could require prior authorization under some benefit plans. 2) Retesting interval and lab hard-stop guidance — Routine repeat measurement of lipase or amylase for disease monitoring is not supported; limit retesting to clinically indicated intervals (e.g., when new/worsening clinical signs occur). Laboratories or ordering systems may implement hard-stop rules to prevent unnecessary duplicate or immediate repeat orders. 3) Overuse of concurrent/serial enzyme testing — Co-ordering lipase and amylase together or ordering both on a routine basis is discouraged due to limited added diagnostic value and increased cost; lipase alone is generally sufficient for initial diagnosis. 4) Clinical documentation supporting testing — Orders must be supported by clinical documentation (eg, abdominal pain consistent with AP, signs of systemic inflammation, or imaging findings) that justify testing and any repeat/serial measurements. 5) Coverage and reimbursement are subject to — Coverage and reimbursement are subject to member benefit terms, medical necessity review, and coding/billing rules; medical records may be requested to substantiate services. 6) Preferred testing approach — Prefer ordering serum lipase alone for initial evaluation of suspected acute pancreatitis; reserve amylase testing for specific clinical circumstances when justified. 7) Order-set preference for lipase — Clinical order sets and electronic medical record defaults should prefer lipase-only testing to reduce co-ordering and unnecessary costs.

Prior authorization awareness for concurrent/serial testing
Retesting interval and lab hard-stop guidance
Overuse of concurrent/serial enzyme testing discouraged
Clinical documentation must support testing and repeats
Coverage and reimbursement subject to benefit terms and medical necessity review
Preferred testing approach: lipase-only for initial evaluation
Order-set preference: set EMR defaults to lipase-only

Provider Actions, Documentation, and Denial Risks

Step Therapy

Prefer serum lipase alone

Order serum lipase alone for diagnosis of suspected acute pancreatitis when available; avoid co‑ordering serum amylase when lipase suffices.

Policy: "measurement of either serum lipase (preferred) or amylase...may be considered reimbursable" for individuals with signs/symptoms of AP.
Evidence and cost studies support preferring lipase alone over co‑ordering amylase.

Step Therapy

Set order‑sets to default to lipase only

Configure order sets and defaults to favor lipase‑only testing; studies summarized in the policy support higher diagnostic accuracy and cost savings from lipase‑only ordering.

Removing amylase from common order sets reduced co‑ordering and produced measurable savings in cited studies.

Step Therapy

Background and Rationale

Acute pancreatitis is an inflammatory condition of the pancreas that can range from mild, self‑limited illness resolving in 1–2 weeks to severe disease requiring hospitalization and intensive care. Diagnosis follows the revised Atlanta classification: at least two of three criteria are required — characteristic abdominal pain, serum amylase or lipase >3× the upper limit of normal, or imaging findings consistent with pancreatitis — and clinical course varies by severity and etiology.

Definitions and Test Characteristics

AP (acute pancreatitis) — definition and revised Atlanta criteria summary

DefinitionAcute pancreatitis (AP) is diagnosed when at least two of: (1) characteristic abdominal pain, (2) serum amylase or lipase >3× ULN, or (3) characteristic findings on contrast-enhanced CT/MRI/ultrasound (Revised Atlanta criteria).

Severity and phasesAP ranges from mild to severe and may be classified as edematous or necrotizing; organ failure duration distinguishes moderate from severe disease.

Guideline basisIAP/APA Working Group (2013) and other societies adopt the Atlanta classification as the diagnostic standard.

Lipase — characteristics and diagnostic window

PhysiologyPancreatic (triacylglycerol) lipase rises within hours after pancreatic injury and is 100-fold higher than other tissue lipases.

Timing

Policy Revision History

2025-10-14policy_approval

Policy approved by the organization (New policy approved October 14, 2025).

2026-02-06effective_dateLatest

Policy became effective for dates of service on or after February 6, 2026, following a 90-day provider notification period.

2025-11-01document_note

Policy Summary

PayerPremera Bluecross

PolicyPancreatic Enzyme Testing for Acute Pancreatitis

Policy CodePolicy G2153

Change TypeMaterial — added routine test management language

Effective DateFeb 6, 2026

Next Review Date

Key ActionOrder serum lipase alone for suspected acute pancreatitis when available; avoid concurrent amylase or routine repeat testing without new clinical indication.

SourceLink

On This Page

Prefer serum lipase as the initial test

When available, use serum lipase as the initial diagnostic test for suspected acute pancreatitis; order amylase only if lipase is not available as a stat test.

AACC recommendation: do not order amylase if serum lipase is available; consider amylase only when lipase is not available as a stat test.

Documentation Required

Document signs/symptoms to support testing

Document clinical signs or symptoms consistent with acute pancreatitis and, when applicable, include enzyme elevations or imaging findings to support testing.

Note 1 lists qualifying signs/symptoms (eg, epigastric pain, nausea, vomiting, abdominal tenderness).
Policy requires documentation of presenting signs/symptoms of AP to consider reimbursement for lipase or amylase.

Documentation Required

Document Atlanta diagnostic criteria

Document that the diagnosis meets the Atlanta criteria—at least two of characteristic abdominal pain, serum amylase or lipase ≥3× ULN, or imaging confirmation.

Policy cites the two‑of‑three diagnostic criterion aligned with the revised Atlanta classification.

Documentation Required

Document enzyme threshold and timing

Record serum amylase or lipase values when they are ≥3× the laboratory upper limit of normal as diagnostic evidence and note timing of symptom onset relative to testing.

Diagnostic enzyme threshold per Atlanta and guideline references: ≥3× upper limit of normal.
Guidance emphasizes documenting timing (eg, onset of symptoms vs time of test).

Note

Confirm member benefit limits before ordering

Verify coverage and any applicable limits with the member benefit booklet or customer service before ordering, as reimbursement is subject to the member’s benefit plan.

Policy note: coverage and reimbursement are subject to member benefit plan limits; contact member services to determine applicable benefit limitations.

Denial Risk

Avoid >1 test per visit and asymptomatic screening

Do not expect reimbursement for more than one amylase or lipase measurement per visit and do not order these tests for asymptomatic individuals during a general exam.

Policy: measurement of serum lipase and/or amylase is not reimbursable if performed more than once per visit or for asymptomatic individuals during general exams without abnormal findings.

Denial Risk

Avoid non‑reimbursable biomarker tests

Do not order serum or urine trypsin/trypsinogen/TAP, urinary amylase for initial diagnosis, or biomarkers (CRP, IL‑6, IL‑8, procalcitonin) for diagnosis/assessment—these are listed as not reimbursable.

Policy explicitly lists these tests as not reimbursable due to insufficient evidence of clinical benefit.

Denial Risk

Do not order concurrent or serial enzyme panels routinely

Do not co‑order amylase concurrently with lipase when lipase alone would suffice, and avoid unnecessary serial or repeat enzyme testing without new clinical indication.

Studies cited identify co‑ordering and serial testing as overutilization with measurable cost impact.

Denial Risk

Redundant or repeated testing may be denied

Ordering both amylase and lipase is discouraged; redundant or repeated tests without clinical indication may be denied as unnecessary.

AACC: testing both increases costs while only marginally improving diagnostic efficiency.
CADTH guidance discourages reordering lipase for routine monitoring and supports minimum retesting intervals.

Note

Concurrent/serial testing may trigger review

Be aware that evidence supports lipase‑only testing and that concurrent or serial testing patterns may prompt utilization review even though no formal prior authorization is specified.

Policy notes cost and utilization evidence supporting lipase‑only approaches and flags overuse as subject to management.

Billing Rule

Adhere to retesting intervals; consider lab hard‑stops

Follow minimum retesting interval guidance and consider laboratory hard‑stop policies to prevent routine repeat lipase testing for monitoring established acute or chronic pancreatitis unless new clinical suspicion exists.

CADTH: do not reorder lipase to monitor established AP or chronic pancreatitis; labs may implement a 6‑month hard stop in outpatient settings as an implementation option.

Prior Authorization

No prior authorization specified in policy

No prior authorization statements are provided in this section of the policy.

Coding section lists CPT codes but does not state any prior authorization requirement; the policy elsewhere reiterates no prior‑auth statements present.

Denial Risk

Do not bill for lipase/amylase outside AP indications

Testing for serum lipase or amylase for indications other than individuals presenting with signs and symptoms of acute pancreatitis is not reimbursable and may be denied.

Policy: any use of serum lipase or amylase other than for individuals presenting with signs/symptoms of AP is not reimbursable.

Lipase elevates within ~3–6 hours, usually peaks around 24 hours, and remains elevated for 8–14 days (1–2 weeks).

Diagnostic performanceLipase has higher sensitivity and specificity than amylase for AP and is preferred for initial testing when available.

Amylase — characteristics and limitations

Source and kineticsAmylase is produced by salivary glands and pancreas; it rises early after pancreatic injury but returns to normal more rapidly (half-life ~12 hours).

LimitationsAmylase may be normal in some causes of AP (e.g., hypertriglyceridemia) and elevations occur in many nonpancreatic conditions, reducing specificity.

Clinical implicationBecause amylase normalizes quickly, timing of testing is critical and amylase is less useful than lipase when presentation is delayed.

Lipase elevation — threshold context

Diagnostic contextAn enzyme elevation ≥3× ULN is used by guideline committees (IAP/APA, NASPGHAN) as the enzyme threshold consistent with pancreatitis.

Study variationSome individual studies used lower cutoffs (e.g., 2× URL) and are considered outliers compared with consensus recommendations.

DocumentationRecord exact enzyme values and timing relative to symptom onset when using enzyme elevation as diagnostic evidence.

Trypsinogen-2 dipstick (UTDT) — urine point-of-care test status

Test typeTrypsinogen-2 dipstick (urine) is a point-of-care urine test detecting trypsinogen-2 (UTDT / Actim Pancreatitis test).

Performance and statusReported sensitivities/specificities vary (some studies report high values), but the IAP/APA did not include UTDT due to presumed limited availability and as of 2023 the test is not FDA-approved for AP diagnosis in the U.S.

Clinical roleUTDT and other trypsin/TAP assays have variable utility and are not recommended as primary, validated diagnostic standards in current guidelines.

Diagnostic threshold — biochemical definition (>3× ULN)

Biochemical definitionDiagnostic biochemical threshold: serum amylase or lipase greater than three times the upper limit of normal (>3× ULN).

Use in criteriaThis biochemical threshold constitutes one of the two required criteria (2-of-3) in the Atlanta diagnostic definition of AP.

Guideline supportEndorsed by IAP/APA, AGA, and NASPGHAN as part of diagnostic recommendations.

Preferred test — Serum lipase preferred over amylase for initial diagnosis

Preferred initial testSerum lipase is preferred over amylase for initial diagnosis of suspected acute pancreatitis when available.

RationaleLipase has improved sensitivity/specificity and a longer diagnostic window, reducing missed diagnoses when testing is delayed.

Ordering guidanceAvoid routine concurrent ordering of amylase when lipase alone suffices; consider amylase only if lipase is not available as a stat test.

Document notes 'New policy, approved October 14, 2025, effective for dates of service on or after February 6, 2026' and records the addition to the Routine Test Management Policy section specifying that measurement of serum lipase or amylase may be reimbursable for individuals presenting with signs and symptoms of acute pancreatitis; other uses are not reimbursable.